Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, March 31, 2009.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2009 (2009-03-31): -877.28%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-327.53%
RETURN ON EQUITY (ROE) AVG 3Y
-130.71%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MannKind Corporation
Market Cap
$1.22B
Return on Equity (ROE)
N/A
TTM Avg
-327.53%
3Y Avg
-130.71%
5Y Avg
N/A
Market Cap
$1.22B
Return on Equity (ROE)
-1.08%
TTM Avg
-6.99%
3Y Avg
-9.25%
5Y Avg
-8.69%
Market Cap
$1.23B
Return on Equity (ROE)
6.53%
TTM Avg
1.49%
3Y Avg
-4.63%
5Y Avg
-8.73%
Market Cap
$1.23B
Return on Equity (ROE)
1.70%
TTM Avg
-39.25%
3Y Avg
-48.34%
5Y Avg
-48.34%
Market Cap
$1.24B
Return on Equity (ROE)
-36.81%
TTM Avg
-43.14%
3Y Avg
-42.82%
5Y Avg
-37.59%
Market Cap
$1.27B
Return on Equity (ROE)
N/A
TTM Avg
76.67%
3Y Avg
76.67%
5Y Avg
76.67%
Market Cap
$1.17B
Return on Equity (ROE)
-50.93%
TTM Avg
-117.72%
3Y Avg
-113.46%
5Y Avg
-86.51%
Market Cap
$1.16B
Return on Equity (ROE)
-17.40%
TTM Avg
-189.25%
3Y Avg
-172.42%
5Y Avg
-134.67%
Market Cap
$1.15B
Return on Equity (ROE)
2.51%
TTM Avg
3.60%
3Y Avg
0.50%
5Y Avg
-7.05%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MannKind Corporation (MNKD) | $1.22B | N/A | -327.53% | -130.71% | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.22B | -1.08% | -6.99% | -9.25% | -8.69% |
| Cronos Group Inc. (CRON)vs › | $1.23B | 6.53% | 1.49% | -4.63% | -8.73% |
| Omada Health (OMDA)vs › | $1.23B | 1.70% | -39.25% | -48.34% | -48.34% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | -36.81% | -43.14% | -42.82% | -37.59% |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | 76.67% | 76.67% | 76.67% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | -50.93% | -117.72% | -113.46% | -86.51% |
| Nektar Therapeutics (NKTR)vs › | $1.16B | -17.40% | -189.25% | -172.42% | -134.67% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 2.51% | 3.60% | 0.50% | -7.05% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | N/A | 35.70% | 35.70% | 35.70% |
ROE
N/A
ROA
-6.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2009-03-31 | -877.28% |
| 2008-12-31 | -349.39% |
| 2008-09-30 | -180.36% |
| 2008-06-30 | -132.86% |
| 2008-03-31 | -97.78% |
| 2007-12-31 | -80.52% |
| 2007-09-30 | -161.14% |
| 2007-06-30 | -111.72% |
| 2007-03-31 | -82.51% |
| 2006-12-31 | -60.12% |
| 2006-09-30 | -310.74% |
| 2006-06-30 | -139.10% |
| 2006-03-31 | -80.93% |
| 2005-12-31 | -55.24% |
| 2005-09-30 | -42.40% |
| 2005-06-30 | -91.95% |
| 2005-03-31 | -64.05% |
| 2004-12-31 | -50.54% |
